Caliway Biopharmaceuticals
Caliway Biopharmaceuticals Co., Ltd. is a clinical-stage biopharmaceutical development enterprise based in Taiwan focused on medical aesthetics and inflammatory diseases. The company engages in the research and drug development of small-molecule therapeutics targeting subcutaneous fat reduction, scar prevention, and inflammatory skin conditions. Primary revenue model is focused on long-term drug development milestones, global technology licensing agreements, and eventual commercial sales of proprietary pharmaceutical formulations. Caliway Biopharmaceuticals targets healthcare providers, aesthetic medicine specialists, plastic surgery clinics, and dermatology practices in international markets. The enterprise operates as an emerging developer of novel aesthetic and therapeutic drug candidates within the Asian biopharmaceutical sector. Caliway Biopharmaceuticals Co., Ltd. is headquartered in New Taipei City, Taiwan, and its common shares are listed on the Taiwan Stock Exchange.
11 of the funds FundTelligence covers report a position in Caliway Biopharmaceuticals.
- Legal name
- Caliway Biopharmaceuticals Co. Ltd.
- Sector
- Health Care
- Country
- Taiwan
- Funds holding it
- 11
Funds holding Caliway Biopharmaceuticals
- Danske Invest Global Emerging Markets Index Restricted — Danske Invest · 0.06 % (full portfolio disclosed, July 2026)
- SEB Emerging Markets Exposure — SEB · 0.03 % (full portfolio disclosed, June 2026)
- Lannebo Emerging Markets — Lannebo · 0.03 % (full portfolio disclosed, June 2026)
- KLP AksjeFremvoksende Markeder Indeks — KLP · 0.03 % (full portfolio disclosed, June 2026)
- Handelsbanken Emerging Markets Index — Handelsbanken · 0.02 % (full portfolio disclosed, September 2026)
- BlackRock iShares MSCI EM IMI Screened UCITS ETF — BlackRock · 0.02 % (full portfolio disclosed, October 2026)
- Danske Invest Global AC Index Restricted — Danske Invest · 0.01 % (full portfolio disclosed, July 2026)
- Storebrand Emerging Markets — Storebrand · 0.01 % (full portfolio disclosed, October 2026)
Showing the 8 largest of 11 funds holding it.